Cumulative toxicities from cisplatin therapy and current cytoprotective measures (Q77522856)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9805507 AND SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Cumulative toxicities from cisplatin therapy and current cytoprotective measures (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9805507 AND SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

E Cvitkovic

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9805507 AND SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 August 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9805507 AND SRC:MED&resulttype=core&format=json

6 December 2019

published in

Cancer Treatment Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9805507 AND SRC:MED&resulttype=core&format=json

6 December 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9805507 AND SRC:MED&resulttype=core&format=json

6 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9805507 AND SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

265-281

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9805507 AND SRC:MED&resulttype=core&format=json

Drugs five years later. Cisplatin

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin nephrotoxicity. A review

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Newer insights into cisplatin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin neurotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin-associated neurotoxicity: can it be prevented?

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Re

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Drug treatment of chemotherapy-induced delayed emesis

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

1 reference

7 January 2021

Optimal number of chemotherapy courses in advanced nonseminomatous testicular carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Eastern Cooperative Oncology Group Experience With Chemotherapy in Advanced Non-small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Palliative and adjuvant regional chemotherapy in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

The treatment of metastatic melanoma with chemotherapy and biologics

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Neurotoxicity in a phase I trial of continuous infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

The long-term effect of cisplatin on renal function

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Renal function related to different treatment modalities for malignant germ cell tumours

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Influence of Combination Chemotherapy with <i>cis</i>-Diamminedichloroplatinum on Renal Function: Long-Term Effects

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Long-term renal effect of cisplatin in man

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Long-term effects of chemotherapy in patients with testicular cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin-associated hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Acute and long-term nephrotoxicity of cis-platinum in man.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Renal tubular function in patients treated with high-dose cisplatin

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Long term effect of Cis-Diamminedichloride platinum (CDDP) on renal function and structure in man

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Effect of cisplatin on renal function in rabbits: mechanism of reduced glucose reabsorption

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Adverse effects of anti-tumor drug, cisplatin, on rat kidney mitochondria: disturbances in glutathione peroxidase activity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Stimulation of the renal endoplasmic reticulum calcium pump: a possible biomarker for platinate toxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cumulative renal tubular damage associated with cisplatin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Clearance of iohexol,51Cr-EDTA and endogenous creatinine for determination of glomerular filtration rate in pigs with reduced renal function: A comparison between different clearance techniques

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

The clinical significance of calculated versus measured creatinine clearance in patients with gynecologic malignancy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin‐induced nephrotoxicity and the protective effect of fosfomycin on it as demonstrated by using a crossover study of urinary metabolite levels

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Hypomagnesemia and Renal Magnesium Wasting in Patients Receiving Cisplatin

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

cis-Diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Renal salt wasting in patients treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Persisting renotubular sequelae after cisplatin in children and adolescents

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Ifosfamide plus Cisplatin as Primary Chemotherapy of Advanced Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Ifosfamide, Fanconi's syndrome, and rickets

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Ifosfamide in refractory male germ cell tumors

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

M-VAC combination in locally advanced, locally recurrent or metastatic breast carcinoma. A phase II study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

The clinical pharmacology of methotrexate.new applications of an old drug

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

A prospective study of VEC-POB and POCE chemotherapy in aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Bleomycin in nonseminomatous germ-cell tumors: cure rate versus morbidity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Influence of Platinum-Induced Renal Toxicity on Bleomycin-Induced Pulmonary Toxicity in Patients with Disseminated Testicular Carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Evaluation of long-term toxicity after chemotherapy for testicular cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Severe nephrotoxicity: a probable complication of cis-dichlorodiammineplatinum (II) and cephalothin-gentamicin therapy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin neurotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Detection of platinum in the brain of mice treated with cisplatin and subjected to short-term hypoxia

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Unusual presentation of cis-platinum neuropathy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiaminoplatinum II

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Progressive paresthesias after cessation of therapy with very high-dose cisplatin

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Neuropeptides and Morphological Changes in Cisplatin-Induced Dorsal Root Ganglion Neuronopathy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Study of ORG 2766 in the Prevention or Delay of Cisplatin-Induced Neuropathies in Women with Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Severe, disabling neurologic toxicity following cisplatin retreatment

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

cis-Platinum ototoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Ototoxicity from cis-platinum in patients with stages III and IV previously untreated squamous cell cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Hearing loss in children receiving cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

High-frequency audiometric monitoring strategies for early detection of ototoxicity.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin ototoxicity in gynecologic cancer patients. A preliminary report

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Ototoxicity of cisplatinum in children and adolescents

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cis-platinum vestibular toxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Assessment of cisplatin-induced ototoxicity using derived-band ABRs

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Early detection of cisplatin-induced ototoxicity using evoked otoacoustic emissions

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Differential damage to auditory neurons and hair cells by ototoxins and neuroprotection by specific neurotrophins in rat cochlear organotypic cultures

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin metabolites and their toxicity on isolated cochlear outer hair cells in vitro

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Mechanism of cisplatin ototoxicity: antioxidant system

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Taxol-induced neuropathy: short-term effects of local injection

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Peripheral neurotoxicity of taxol in patients previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

High-Dose Cisplatin in Hypertonic Saline

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Biochemical modulation of cisplatin toxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Effects of radioprotectors on DNA damage and repair, proteins, and cell-cycle progression

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Biological Factors Affecting the Radioprotective Efficiency of S-2-[3-Aminopropylamino] Ethylphosphorothioic Acid (WR-2721). LD 50(30) Doses

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

WR‐1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase IIα leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Phase II Evaluation of Cisplatin and WR2721 for Refractory Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Diethyldithiocarbamate protection against cisplatin nephrotoxicity: antioxidant system

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Mechanism of Protection by Diethyldithiocarbamate against Cisplatin Ototoxicity: Antioxidant System

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Modification of cisplatin toxicity with diethyldithiocarbamate

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Phase I Clinical and Pharmacokinetic Study of Diethyldithiocarbamate as a Chemoprotector From Toxic Effects of Cisplatin

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin nephrotoxicity: diethyldithiocarbamate, WR2721, or just water?

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Glutathione-dependent antioxidant systems in the mammalian inner ear: effects of aging, ototoxic drugs and noise

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

The fate of extracellular glutathione in the rat☆

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Antioxidant and glutathione-related enzymatic activities in rat sciatic nerve

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Protection against cisplatin toxicity by administration of glutathione ester

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Phase I trial of cisplatin in combination with glutathione

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

A feasibility study of high-dose cisplatin and 5-fluorouracil with glutathione protection in the treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Kinetics of sodium thiosulfate, a cisplatin neutralizer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Inactivation of cis-diamminedichloroplatinum (II) in blood and protection of its toxicity by sodium thiosulfate in rabbits

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Mechanism of the Protective Effect of Sodium Malate on Cisplatin-Induced Toxicity in Mice

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

High-dose cisplatin with sodium thiosulfate protection.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

First line immunochemotherapy with cisplatin-based protocol by intraperitoneal and intravenous routes in ovarian cancer: technique and results of 82 cases

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensity.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Intraperitoneal cisplatin with systemic thiosulfate protection

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperativ

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Enhancement of regeneration by Org 2766 after nerve crush depends on the type of neural injury

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Co-administration of the neurotrophic ACTH(4-9) analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Protective effect of fosfomycin against aminoglycoside ototoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Pantothenic acid and coenzyme A in experimental cisplatin-induced ototoxia

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

4-Methylthiobenzoic acid reduces cisplatin nephrotoxicity in rats without compromising anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Protection by 4‐Methylthiobenzoic Acid Against Cisplatin‐Induced Ototoxicity: Antioxidant System

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-deriv

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Neurotrophin-4/5, brain-derived neurotrophic factor, and neurotrophin-3 promote survival of cultured vestibular ganglion neurons and protect them against neurotoxicity of ototoxins

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Protection of both auditory hair cells and auditory neurons from cisplatin induced damage.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

D-methionine provides excellent protection from cisplatin ototoxicity in the rat.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Neurotrophin‐3 reverses experimental cisplatin‐induced peripheral sensory neuropathy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Failure of a 21-Aminosteroid Antioxidant to Ameliorate Cisplatin-Induced Nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Protective Effects of Betamipron on Renal Toxicity During Repeated Cisplatin Administration in Rats and Protective Mechanism

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

The use of probenecid as a chemoprotector against cisplatin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

Protective role of metallothionein in renal toxicity of cisplatinum

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(98)90061-5

7 January 2021

10.1016/S0305-7372(98)90061-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9805507 AND SRC:MED&resulttype=core&format=json

6 December 2019

1 reference